Moderna and Merck advance personalized cancer shot after late-stage melanoma trial cuts recurrence risk

Merck and Moderna announced that their personalized mRNA cancer vaccine reduced the risk of death or recurrence by 42 percent compared to standard care in a Phase 3 trial. The treatment specifically targets melanoma, the deadliest form of skin cancer, and relies on tailoring the medicine to a patient's individual tumor. [1][2]

Following the late-stage trial results, both pharmaceutical companies are actively engaging with regulatory authorities to secure marketing approval for the vaccine. Moderna chief executive Stéphane Bancel described the milestone as a defining moment for mRNA technology, stating that creating therapies uniquely matched to a tumor represents a fundamental shift in cancer treatment. [2]